The DOI matches its Crossref record.
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Abstract
No AccessJournal of Urology1 Aug 1976Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors A. Morales, D. Eidinger, and A.W. Bruce A. MoralesA. Morales Current address: Laboratory of Immunodiagnosis, Building 8, Room 118, National Institutes of Health, Bethesda, Maryland, 20014. More articles by this author , D. EidingerD. Eidinger More articles by this author , and A.W. BruceA.W. Bruce More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)58737-6AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin. The pattern of recurrence in 9 patients has been altered favorably. Although the findings are still preliminary they appear to hold promise of a new therapeutic approach to the treatment of a group of neoplasms for which effective therapy is still lacking. © 1976 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byDonin N, Lenis A, Holden S, Drakaki A, Pantuck A, Belldegrun A and Chamie K (2018) Immunotherapy for the Treatment of Urothelial CarcinomaJournal of Urology, VOL. 197, NO. 1, (14-22), Online publication date: 1-Jan-2017.Droller M (2016) Intracavitary bacillus Calmette-Guérin for Superficial Bladder TumorsJournal of Urology, VOL. 197, NO. 2S, (S146-S147), Online publication date: 1-Feb-2017.Yokomizo A, Kanimoto Y, Okamura T, Ozono S, Koga H, Iwamura M, Tanaka H, Takahashi S, Tsushima T, Kanayama H, Akaza H, Shinohara N, Mugiya S, Nomata K, Nakamura T and Naito S (2018) Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 195, NO. 1, (41-46), Online publication date: 1-Jan-2016.Gan C, Amery S, Chatterton K, Khan M, Thomas K and O’Brien T (2018) Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year OutcomesJournal of Urology, VOL. 195, NO. 6, (1697-1703), Online publication date: 1-Jun-2016.Holmäng S (2018) Patients with High Grade Bladder Cancer, and Tumor-Free 3 and 6-Month Cystoscopy after bacillus Calmette-Guérin have a Good Prognosis without Further Maintenance bacillus Calmette-GuérinUrology Practice, VOL. 3, NO. 1, (50-54), Online publication date: 1-Jan-2016.Barlow L, McKiernan J and Benson M (2018) Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin TherapyJournal of Urology, VOL. 189, NO. 3, (834-839), Online publication date: 1-Mar-2013.Johnson M, Nepple K, Peck V, Trinkaus K, Klim A, Sandhu G and Kibel A (2018) Randomized Controlled Trial of Oxybutynin Extended Release Versus Placebo for Urinary Symptoms During Intravesical Bacillus Calmette-Guérin TreatmentJournal of Urology, VOL. 189, NO. 4, (1268-1274), Online publication date: 1-Apr-2013.Brausi M, Witjes J, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H and Böhle A (2018) A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer GroupJournal of Urology, VOL. 186, NO. 6, (2158-2167), Online publication date: 1-Dec-2011.Alvarez-Múgica M, Cebrian V, Fernández-Gómez J, Fresno F, Escaf S and Sánchez-Carbayo M (2018) Myopodin Methylation is Associated With Clinical Outcome in Patients With T1G3 Bladder CancerJournal of Urology, VOL. 184, NO. 4, (1507-1513), Online publication date: 1-Oct-2010.DeCastro G and Steinberg G (2018) Are We Making Significant Progress in the Diagnosis and Management of Bladder Cancer?Journal of Urology, VOL. 183, NO. 5, (1667-1668), Online publication date: 1-May-2010.Nepple K, Lightfoot A, Rosevear H, O'Donnell M and Lamm D (2018) Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 184, NO. 5, (1915-1919), Online publication date: 1-Nov-2010.Rosevear H, Lightfoot A, Nepple K and O'Donnell M (2018) Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Plus Interferon α-2b Therapy for Nonmuscle Invasive Bladder Cancer in Patients With Prosthetic DevicesJournal of Urology, VOL. 184, NO. 5, (1920-1924), Online publication date: 1-Nov-2010.Bisiaux A, Thiounn N, Timsit M, Eladaoui A, Chang H, Mapes J, Mogenet A, Bresson J, Prié D, Béchet S, Baron C, Sadorge C, Thomas S, Albert E, Albert P and Albert M (2018) Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 17
- Veenema, 1969, Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors, J. Urol., 101, 711, 10.1016/S0022-5347(17)62408-X · doi:10.1016/s0022-5347(17)62408-x
- Riddle, 1973, The management of superficial bladder tumours with intravesical epodyl, Brit. J. Urol., 45, 84, 10.1111/j.1464-410X.1973.tb00048.x · doi:10.1111/j.1464-410x.1973.tb00048.x
- Durrant, 1975, Treatment of multiple superficial papillary tumors of the bladder by intracavitary yttrium-90, J. Urol., 113, 480, 10.1016/S0022-5347(17)59505-1 · doi:10.1016/s0022-5347(17)59505-1
- Bubenik, 1970, Immune response to urinary bladder tumours in man, Int. J. Cancer, 5, 39, 10.1002/ijc.2910050106 · doi:10.1002/ijc.2910050106
- Catalona, 1973, Correlation among host immunocompetence and tumor stage, tumor grade and vascular permeation in transitional carcinoma, J. Urol., 110, 526, 10.1016/S0022-5347(17)60270-2 · doi:10.1016/s0022-5347(17)60270-2
- Zbar, 1974, Immunotherapy of guinea pig cancer with BCG, Cancer, 34, 1532, 10.1002/1097-0142(197410)34:8+<1532::AID-CNCR2820340827>3.0.CO;2-H · DOI
- Jondal, 1973, Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells, J. Exp. Med., 136, 207, 10.1084/jem.136.2.207 · doi:10.1084/jem.136.2.207
- Ferluga, 1973, Increased cytolytic activity of a subcellular fraction from mouse liver after B.C.G. injection, Lancet, 2, 1476, 10.1016/S0140-6736(73)92734-7 · DOI
- Gutterman, 1973, BCG stimulation of immune responsiveness in patients with malignant melanoma, Cancer, 32, 321, 10.1002/1097-0142(197308)32:2<321::AID-CNCR2820320207>3.0.CO;2-Y · doi:10.1002/1097-0142(197308)32:2<321::aid-cncr2820320207>3.0.co;2-y
- Grant, 1974, Results of administering B.C.G. to patients with melanoma, Lancet, 2, 1096, 10.1016/S0140-6736(74)90867-8 · doi:10.1016/s0140-6736(74)90867-8
- Donaldson, 1973, Chemoimmunotherapy for cancer of the head and neck, Amer. J. Surg., 126, 507, 10.1016/S0002-9610(73)80040-6 · doi:10.1016/s0002-9610(73)80040-6
- Morales, 1976, Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney, J. Urol., 115, 377, 10.1016/S0022-5347(17)59210-1 · doi:10.1016/s0022-5347(17)59210-1
- Bloomberg, 1975, The effects of BCG on the dog bladder, Invest. Urol., 12, 423
- Hanna, 1972, Histopathology of Mycobacterium bovis (BCG)-mediated tumor regression, Nat. Cancer Inst. Monogr., 35, 345
- Falk, 1973, Cell-mediated immunity to human tumors. Abrogation by serum factors and nonspecific effects of oral BCG therapy, Arch. Surg., 107, 261, 10.1001/archsurg.1973.01350200123026 · doi:10.1001/archsurg.1973.01350200123026
- Morales, 1976, Immune reactivity in renal cancer: a sequential study, J. Urol., 115, 510, 10.1016/S0022-5347(17)59261-7 · doi:10.1016/s0022-5347(17)59261-7
- Papatestas, 1974, Peripheral lymphocyte counts in breast carcinoma. An index of immune competence, Cancer, 34, 2014, 10.1002/1097-0142(197412)34:6<2014::AID-CNCR2820340620>3.0.CO;2-Q · doi:10.1002/1097-0142(197412)34:6<2014::aid-cncr2820340620>3.0.co;2-q
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
The mechanism of action of BCG therapy for bladder cancer--a current perspective
Redelman-Sidi, G., Glickman, M. S., & Bochner, B. H. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.15 · Cited by 729
Inflammation as a Tumor Promoter in Cancer Induction
Philip, M., Rowley, D. A., & Schreiber, H. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.006 · Cited by 640
Metadata
- Authors
- Morales, A., Eidinger, D., & Bruce, A. W.
- Venue
- Journal of Urology
- Published
- 1976-08
- Volume
- 116
- Issue
- 2
- Pages
- 180-182
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W4243650202
- Cited by
- 1,791
- References
- 0
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors. https://app.cochat.ai/papers/10.1016/s0022-5347(17)58737-6
- The paper
- Morales, A., Eidinger, D., & Bruce, A. W. (1976). Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors. Journal of Urology. https://doi.org/10.1016/s0022-5347(17)58737-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
